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Abstract: The ATP-dependent uptake of L-glutamate into 
synaptic vesicles has been well characterized, implicating a 
key role for synaptic vesicles in glutarnatergic neurotrans- 
mission. In the present study, we provide evidence that ve- 
sicular glutamate uptake is selectively inhibited by the pep- 
tide-containing halogenated ergot bromocriptine. It is the 
most potent inhibitor of the agents tested; the ICso was de- 
termined to be 22 pM. The uptake was also inhibited by 
other ergopeptines such as ergotamine and ergocristine, but 
with less potency. Ergots devoid of the peptide moiety, how- 
ever, such as ergonovine, Iergotrile, and methysergide, had 
little or no effect. Although bromocriptine is known to elicit 
doparninergic and serotonergic effects, its inhibitory effect on  
vesicular glutamate uptake was not mimicked by agents 
known to interact with dopamine and serotonin receptors. 
Kinetic data suggest that bromocriptine competes with glu- 
tarnate for the glutamate binding site on the glutamate trans- 
locator. It is proposed that this inhibitor could be useful as 
a prototype probe in identifying and characterizing the ve- 
sicular glutamate translocator, as well as in developing a more 
specific inhibitor of the transport system. Key Words: Glu- 
tamate-Synaptic vesicle-ATP-dependent uptake-Er- 
gots-Competitive inhibition-Glutamate translocator. 
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It is now widely accepted that glutamate functions 
as a major excitatory neurotransmitter in the vertebrate 
CNS (for reviews see Watkins and Evans, 1981; Cot- 
man et al., 198 1 ; Fonnum, 1984; Ueda, 1986; Cotman 
et al., 1987; Nicholls, 1989) and at the neuromuscular 
junction of arthropods (Usherwood, 198 1). The neu- 
rotransmitter glutamate is released from nerve termi- 
nals on their depolarization in a calcium-dependent 
manner (Bradford et al., 1973; Reubi and Cuknod, 
1979; Cotman et al., 198 1 ; Levi et al., 1982). Nicholls 
and Sihra (1986) have provided evidence that a non- 
cytosolic pool of glutamate is rapidly released in a Ca2+- 
dependent manner, suggesting a role for synaptic ves- 
icles in glutamate synaptic transmission. Glutamate 
has been shown to be specifically taken up into highly 
purified, isolated synaptic vesicles in an ATP-depen- 
dent manner (Naito and Ueda, 1983, 1985; Maycox 
et al., 1988), in accord with the immunocytochemical 
evidence that glutamate is concentrated in synaptic 
vesicles in certain nerve endings that are distinct from 
y-aminobutyric acid (GABA)-rich nerve terminals 
(Storm-Mathisen et al., 1983). The vesicular glutamate 
uptake is driven by an electrochemical proton gradient, 
which is generated by a proton pump Mg-ATPase, and 
stimulated by physiologically relevant concentrations 
ofchloride (Naito and Ueda, 1985; Maycox et al., 1988; 
Shioi et al., 1989). The high degree of specificity and 
the unique properties of the vesicular glutamate uptake 
system have led to the proposal that whether or not 
glutamate is utilized as a neurotransmitter is deter- 
mined by the presence or absence of the glutamate- 
specific vesicular translocator (Ueda, 1986). Recent 
studies by Fischer-Bovenkerk et al. (1988) suggest that 
the vesicular glutamate system is present in cerebellar 
granule cells, which are considered to be glutamatergic, 
but not in GABAergic Purkinje cells. Moreover, such 
a vesicular uptake system has been shown to develop 
in close parallel with the time course of synaptogenesis 
( a s h  et al., 1989~). These lines of evidence all point 
to the importance of the vesicular glutamate uptake 
system in glutamate synaptic transmission. In this 
study, we have begun to investigate pharmacological 
Received January 30, 1989; revised manuscript received May 16, 
1989; accepted May 17, 1989. 
Address correspondence and reprint requests to Dr. T. Ueda at 
Mental Health Research Institute, The University of Michigan, 205 
Washtenaw Place, Ann Arbor, MI 48109, U.S.A. 
Abbreviations used: GABA, y-aminobutyric acid; RCSV. rat crude 
synaptic vesicles. 
1889 
1890 M. D. CARLSON ET AL. 
means by which the vesicular glutamate transport sys- 
tem can be modulated. We provide evidence suggesting 
that the peptide-containing halogenated ergot bro- 
mocriptine may serve as a prototype agent for devel- 
oping a more specific, potent regulator of the vesicular 
glutamate transport system. 
MATERIALS AND METHODS 
Materials 
L-Glutamic acid (potassium salt), ATP, bromocriptine, a- 
ergocriptine, ergonovine, and ergotamine tartrate were pur- 
chased from Sigma. Ergocristine methanesulfonate and di- 
hydroergocriptine (Sandoz Pharmaceuticals) were generously 
provided by Dr. Edward Domino, Department of Pharma- 
cology, the University of Michigan. Huphenazine was a gift 
from E. R. Squibb and Sons, Princeton. NJ, U.S.A.; chlor- 
promazine was from Smith, Kline, and French, Philadelphia. 
PA, U.S.A.; and lergotrile was from Eli Lilly, Indianapolis, 
IN, U.S.A. Methysergide, trifluoperazine. sulpiride. lysergic 
acid diethylamide, and bromolysergc acid diethylamide were 
provided by Dr. James Woods, Department of Pharmacology. 
the University of Michigan. ~-[2,3-~H]Glutamic a id (36 Ci/ 
mmol), 4-arnin0-n-[2,3-~H]butyric acid (50 Ci/mmol), and 
[2-3H]glycine (I9 Ci/mmol) were obtained from Amersham. 
Preparation of synaptic vesicles 
Rat crude synaptic vesicles (RCSV) were prepared as de- 
scribed by Kish and Ueda (1989). In brief, rat cerebrum was 
homogenized in solution A (0.32 M sucrose, 0.5 mM calcium 
acetate, 1 mM magnesium acetate, and 1 mM NaHC03) and 
centrifuged at 12,100 g,,, for 20 min (10,000 rpm, Sorvall 
SS-34 rotor). The pellet was lysed for 45 rnin in 6 mM Tris- 
maleate (pH 8.1) and centrifuged at 43,500 g,,, for 15 rnin 
( 1  9,000 rpm, Sorvall SS-34 rotor). The supernatant was cen- 
trifuged at 200,000 g,,, for 50 rnin (47,000 rpm, Beckman 
TI 50 rotor) to pellet the synaptic vesicles. This crude vesicle 
preparation, which was resuspended in solution €3 (0.32 M 
sucrose, 1 mM dithiothreitol, 1 mM NaHC03), was used in 
most of the experiments to be described here, except where 
otherwise indicated. Although there was some ATP-indepen- 
dent glutamate uptake activity in the RCSV preparation, it 
represented only about 10% of the ATP-dependent uptake 
activity. 
Assay for vesicular glutamate uptake 
Vesicular glutamate uptake was assayed essentially as de- 
scribed previously by Naito and Ueda (1983, 1985). The 
standard incubation mixture for the glutamate uptake con- 
tained, in a final volume of 100 pl, 50 fig of RCSV, 5 mM 
Tris-maleate (pH 7.4), 4 mM MgS04, 0.25 M sucrose, 2 mM 
L-aspartate, 0 or 2 mM ATP neutralized with Tris-base, 4 
mM KCI, and 50 pM potassium ~-['H]glutamate (0.4 Ci/ 
mmol). Aspartate was included to block any glutamate uptake 
into resealed plasma membrane vesicles, and to block any 
binding to glutamate receptors occurring from any plasma 
membrane contamination in the crude synaptic vesicle prep- 
aration used in these experiments. Synaptic vesicles (10 pl 
containing approximately 50 pug of protein) and the Tris/ 
sucrose medium (70 pl) were preincubated at 30°C for 5 rnin 
and then mixed with 20 pl of a prewarmed glutamate/ATP 
mixture including the KCI and [3H]glutamate. The mixture 
was incubated for an additional 1.5 min. The glutamate up- 
take was terminated by the addition of 2.0 ml of ice-cold 
0.15 M KCI, followed by immediate filtration through Mil- 
lipore H A W  filters (25 mm, 0.45 pm). The incubation tubes 
were washed with the KCl solution three times, and the filters 
were then washed four more times. Radioactivity retained 
on the filters (dpm) was determined in ACS (Amersham) by 
using a liquid scintillation spectrophotometer (Beckman LS 
9000). The amounts of radioactive glutamate nonspecifically 
bound to the filters were determined as follows: the pre- 
warmed [3H]glutamate/ATP mixture was mixed with 2.0 ml 
of KCI solution and filtered; the filters were then washed with 
the KCI solution five more times. The radioactivity retained 
on the filters (400-900 dpm) was subtracted from all of the 
values presented in the uptake experiments described here. 
The means 2 SEM of triplicate determinations were pre- 
sented. All glutamate uptake values presented represent ATP- 
dependent uptake activity, which was defined as the activity 
observed in the presence of ATP minus the activity observed 
in its absence, unless otherwise indicated. Synaptic vesicle 
protein was determined according to Lowry et al. (195 1) with 
bovine serum albumin used as standard. 
RESULTS 
Effects of ergots on vesicular glutamate uptake 
Figure 1 A and B shows the results of an experiment 
in which a number of derivatives of ergot alkaloids 
were tested for their effects on the ATP-dependent up- 
take of glutamate into RCSV. Bromocriptine, an ergot 
with dopamimetic properties (Fuxe et al., 1978; Ke- 
babian and  Calne, 1979), in micromolar concentra- 
tions, caused a marked inhibition of ATP-dependent 
glutamate uptake into RCSV. Bromocriptine was the 
most potent inhibitor of glutamate uptake of the var- 
ious ergot derivatives tested, with an ICS0 of 22 + 6 
pM. ICS0 values (the concentration of inhibitor that 
inhibited 50% of the ATP-dependent glutamate uptake 
activity) were obtained by log-logit transformation of 
the data in Fig. 1A and B. In other experiments not 
shown here, however, the potent dopamine agonist 
apomorphine (100 p M )  did not inhibit glutamate up- 
take. Moreover, inhibition of glutamate uptake was 
not observed with any  of the dopamine antagonists 
tested (at concentrations up to 500 pUn4): trifluopera- 
zine, fluphenazine, chlorpromazine, and sulpiride (data 
not shown). In addition, this inhibitory effect on glu- 
tamate uptake by bromocriptine was not mimicked by 
any of the serotonergic agonists or antagonists tested 
(at 500 p M ) :  lysergic acid diethylamide, bromolysergic 
acid diethylamide, and methysergide (not shown). 
These observations suggest that the inhibitory effect of 
bromocriptine is not mediated through dopamine or 
serotonin receptor mechanisms. 
Bromocriptine is structurally classified as a peptide 
alkaloid or ergopeptine, containing a peptide moiety 
attached to  the ergoline ring structure (Rall and Schlei- 
fer, 1980). To determine whether the inhibitory effect 
of bromocriptine is attributable to the ergoline ring 
structure, the peptide moiety, or to both, the various 
ergot compounds were tested for their ability to inhibit 
the ATP-dependent glutamate uptake. As shown in 
Fig. I ,  those ergots that possess peptide moieties, e.g., 
ergotamine (ICS0 = 30 * 2 p M ) ,  a-ergocriptine 
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FIG. 1. Effects of various concentrations of ergots on ATP-dependent glutamate uptake into synaptic vesicles. A: Glutamate uptake was 
determined in the presence of various concentrations of bromocriptine (O), a-ergocriptine (A), ergotamine (m), and dihydroergocriptine (A). 
B: Glutarnate uptake was determined in the presence of various concentrations of bromocriptine (@), ergocristine (U), ergonovine (0), and 
lergotrile (+), as described in Materials and Methods. [3H]Glutamate uptake activity is expressed as percent of the activity in the absence 
of test agent (control). The glutamate uptake in the control was 11.5 +- 0.24 pmol/l.5 min. All of the ergots except ergonovine and lergotrile 
were dissolved in 50% or 75% (for a-ergocriptine only) ethanol to make a stock solution of 10 mM. Ethanol alone at a concentration of 
0.5% (the concentration used for M ergot), or less, had no effect on glutamate uptake. Ethanol at 2.5%, the concentration used for 
500 pM ergot, lowered the glutamate uptake 42%. This control value was used to determine the effect of this concentration of water- 
insoluble ergot. The data on bromocriptine and the other ergots are representative of five and three individual experiments, respectively. 
The various ergots inhibited the ATP-independent uptake 5-1 0% only at the two highest concentrations of ergot tested (100 and 500 pM). 
= 57 k 10 p M ) ,  dihydroergocriptine (IC50 = 7 3  & 3 
pM),  and ergocristine (IC5,, = 83 * 9 pM),  were all 
effective but less potent than bromocriptine in inhib- 
iting glutamate uptake. In contrast, those ergots that 
lack peptide moieties, such as lergotrile (ICsO > 500 
p M )  and ergonovine (I& > 1 mM), had little or no 
effect. The presence of the bromine moiety also appears 
absence of ATP might represent glutamate binding to 
nonvesicular membrane proteins and/or to enzymes 
involved in the metabolism of glutamate. In an effort 
to determine whether bromocriptine interacts with the 
glutamate translocator component, kinetic experiments 
were carried out in the absence and presence of 10 and 
20 uM bromocriptine. As shown in Fig. 3 ,  the V,,, of 
to enhance- the potency of the inhibitory kffect on glu- 
tical to bromocriptine except that it lacks the bromine 
moiety, has a reduced potency. Therefore, it appears 
that both the peptide and bromine moieties attached 
tamate uptake, because a-ergocriptine, which is iden- 40 
w 30 
Y -  a .E 
+ 2  
to the ergoline ring structure are important in causing 
a potent and selective inhibition of ATP-dependent 
glutamate uptake. 5: 
Nature of the bromocriptine inhibition 
in the absence and presence of bromocriptine, following 5: the standard 5-min preincubation time with the ergot. 
k ?  20 a 
a $  
0 -  
IS Figure 2 shows a time course of glutamate uptake 
10 Bromocriptine showed its inhibitory effect throughout 
the incubation times tested; however, the effect de- 
creased in magnitude with increasing incubation time. 
A preincubation time of 30 s is sufficient to achieve a 
maximal inhibitory effect by a given concentration of 
bromocriptine (data not shown), suggesting that full TIME (min) 
interaction between bromocriptine and a component 
of the glutamate uptake system occurs within 30 s .  
FIG. 2. Time course of vesicular glutamate uptake in the presence 
or absence of bromocriptine. Synaptic vesicles were preincubated 
Figure 2 also shows that bromocriptine inhibited 
glutamate uptake but had no signifi- 
at 30°C for 5 rnin in the absence (0, 0) or presence (m, 0 )  of 100 
pM bromocriptine. A mixture of [3H]glutamate with ATP (0, m) or 
without ATP (0, 0) was then added, and glutamate uptake was 
allowed to occur for the various times indicated. The data are cant effect On ATP-independent uptake. The 
(approximately 2 pmo1/50 p g  protein) obtained in the representative of two individual experiments. 
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glutamate uptake was determined to be 0.26 k 0.02 
nmol/min in both the absence and presence of 10 or 
20 pM bromocriptine. Corresponding K, values were 
2.05 k 0.04, 4.41 * 0.06, and 6.10 f 0.09 mM, re- 
spectively. Thus, the inhibitory action of bromocriptine 
is reflected in a change (increase) in the K, for gluta- 
mate, and not in changes in the V,,, of the uptake 
system. These results suggest that the nature of the in- 
hibitory effect on glutamate uptake by bromocriptine 
is competitive with respect to glutamate. 
Other experiments not presented in this study failed 
to support the possibility that bromocriptine inhibits 
glutamate uptake by inhibiting the Mg-ATPase hydro- 
lysis activity in the synaptic vesicle. Bromocriptine ( 1 - 
100 p M )  exhibited no effect on the Mg-ATPase activity. 
Moreover, the degree of the bromocriptine inhibition 
was not affected by varying the concentration of ATP 
from 0.05 to 2 mM. These studies lend further support 
to the notion that the glutamate translocator is the site 
of action of bromocriptine. 
Effect of bromocriptine on ATP-dependent vesicular 
uptake of GABA and glycine 
The amino acids GABA and glycine are also taken 
up into synaptic vesicles in an ATP-dependent manner 
(Kish et al., 1987, 1988, 19896; Fykse and Fonnum, 
1988; Hell et a]., 1988). These uptake systems are dis- 
tinct from each other and from the glutamate uptake 
system ( a s h  et al., 19896). In an effort to substantiate 
the selective action of bromocriptine on the glutamate 
translocator, we have examined the effect of the ergot 
on the ATP-dependent vesicular uptake of GABA and 
6o 1 
50 - 
C .- . 
E 
0 0.5 1 0  1 5  2.0 
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FIG. 3. Effect of bromocriptine on the kinetic parameters of the 
ATP-dependent vesicular uptake of glutamate. The vesicular glu- 
tamate uptake was determined at various concentrations of glu- 
tamate (0.5-5 rnM) in the absence (0) or presence of 10 pM bro- 
mocriptine (m) or 20 p M  bromocriptine (A), as described in Materials 
and Methods. Specific activities of [3H]glutamate were 0.04 Ci/ 
mmol for 0.5 mM; 0.027 Cipnmol for 0.75 mM; and 0.05, 0.025, 
0.013, and 0.01 Ci/rnmol for 1, 2, 4, and 5 rnM glutamate, re- 
spectively. The data are representative of three individual experi- 
ments. Intercepts were determined by linear regression analysis. 
glycine in comparison with the effect on vesicular glu- 
tamate uptake. As shown in Table 1, the inhibitory 
effect of bromocriptine is greater on the glutamate up- 
take system than on the GABA and glycine uptake 
systems. There was some inhibition by bromocriptine 
of the ATP-independent uptake activity; the inhibition 
of glutamate uptake in the cerebral synaptic vesicles 
and spinal cord vesicles was 2 and 8%, respectively, 
and the inhibition for both GABA and glycine uptake 
was 8%. These results suggest that the inhibitory action 
of bromocriptine is selective for the ATP-dependent 
glutamate uptake system. 
DISCUSSION 
In this study, we have demonstrated that bromo- 
criptine selectively inhibits the ATP-dependent gluta- 
mate uptake into synaptic vesicles. The kinetic data 
shown in Fig. 3 indicate that the nature of bromocrip- 
tine’s inhibitory action on uptake is competitive, with 
respect to glutamate, in that the V,,, of glutamate up- 
take is unchanged, whereas the K, for glutamate is 
increased. These results suggest that bromocriptine is 
acting at the glutamate translocator site of the synaptic 
vesicle, thereby preventing the uptake of glutamate into 
synaptic vesicles. 
Bromocriptine’s competitive interaction at the glu- 
tamate translocator site is substantiated further by 
studies that demonstrated that increasing the concen- 
tration of glutamate attenuated bromocriptine’s ability 
to inhibit the vesicular glutamate uptake (data not pre- 
sented). The competitive inhibition of glutamate up- 
take by bromocriptine also appears to be reversible, 
because removal of bromocriptine by centrifugation 
followed by incubation and subsequent centrifugation 
of the synaptic vesicles in the presence of high concen- 
trations of glutamate (e.g., 50 mM) reversed the in- 
hibitory effect of bromocriptine (not shown). This sup- 
ports the view that the bromocriptine interaction with 
the glutamate translocator is via noncovalent bonding. 
Other experiments not presented in this study sug- 
gested that bromocriptine does not inhibit the Mg- 
ATPase hydrolysis activity in the synaptic vesicle. In 
addition, using the fluorescent probes Oxonol VI and 
Acridine Orange, which are indicators of membrane 
potential (Russell, 1984) and pH gradients (Xie et al., 
19831, respectively, we observed that bromocriptine 
had no detectable effect on the membrane potential or 
pH gradient across the synaptic vesicle membrane (re- 
sults not shown). 
Although bromocnptine is known to mimic some 
of the dopaminergic and serotonergic effects, this study 
indicates that the inhibitory effect on vesicular gluta- 
mate uptake is not attributable to its dopaminergic and 
serotonergic properties. The data in Fig. 1 demonstrate 
that the tripeptide moiety of bromocriptine is crucial 
in achieving potent inhibition of glutamate uptake. 
Thus, ergonovine, which is devoid of the peptide 
moiety, exhibited no effect even at 1 mM, the highest 
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TABLE 1 .  Efect of bromocriptine on ATP-dependent amino acid 
neurotransmitter uptake into synaptic vesicles 
ATP-dependent uptake (dpm/5 min) 
Source of Amino acid Inhibition 
synaptic vesicles neurotransmitters - Bromocriptine + Bromocriptine (%) 
Cerebrum Glutamate 82,825 i 1,542 21,565 f 373 74 
GABA 3,145 k 305 2,284 _i 307 27 
Spinal cord Glutamate 79,216 f 1,294 28,947 +- 860 63 
Glycine 13,032 f 932 9,322 k 601 28 
In the experiments in the upper half, crude synaptic vesicles were prepared from rat cerebrum as described by ffish 
and Ueda (1 989) and purified further by discontinuous sucrose-density gradient (0.4,0.6, and 0.8 Msucrose) centrifugation 
at 141,400 g,, for 120 min (28,000 rpm, SW 28 rotor), and 100 pg of vesicle protein were used per assay. In those in 
the lower half, synaptic vesicles were purified from rat spinal cord by Percoll-density gradient centrifugation as described 
by Kish et al., (19896), and 150 pg of vesicle protein were used per assay. Vesicular amino acid uptake was assayed as 
described previously by Kish et al. (19896), using 150 F M  ~-[~H]glutamate, [3H]GABA, or ['Hlglycine (each 0.13 Ci/ 
mmol), using 10 mM ATP in the absence or presence of 100 p M  bromocriptine (in 0.5% ethanol) in the standard 
incubation medium described for glutamate uptake in Materials and Methods, except that 0.5% ethanol was included 
in the control and the assay volume was 200 pl. Uptake was allowed to occur for 5 min at 30°C. The data are 
representative of two separate experiments; the variation in the percent inhibition from this experiment was 5- 14%. 
concentration tested, whereas all the ergots containing 
the peptide moiety tested are capable of inhibiting the 
glutamate uptake at much lower concentrations. The 
bromine moiety appears to enhance the inhibitory po- 
tency. 
Consistent with the notion that bromocriptine in- 
teracts with the vesicular glutamate translocator is ev- 
idence that the halogenated ergot selectively inhibited 
the glutamate uptake. Thus, GABA and glycine uptakes 
were less affected (Table 1). In addition to its interaction 
with the vesicular glutamate uptake system, bromo- 
criptine has been reported to inhibit the high-affinity 
glutamate reuptake system in striatal membranes 
(Nieoullon et al., 1982). However, in contrast to its 
effect on the vesicular uptake system, the inhibition 
appeared to be achieved through activation of D2-like 
dopamine receptors located on the presynaptic corti- 
costriatal glutamatergic nerve endings. The authors 
proposed that nigrostriatal dopaminergic input may 
regulate corticostriatal glutamatergic activity. We have 
also observed the inhibitory effect of bromocriptine on 
the sodium-dependent glutamate uptake into synap- 
tosomes; in our experiments, 20 pLM bromocriptine in- 
hibited about 30% of the glutamate uptake into syn- 
aptosomes in the presence of 50 pA4 glutamate. The 
glutamate reuptake system located on synaptosomal 
plasma membranes has quite different characteristics 
from the vesicular glutamate uptake system, particu- 
larly with respect to its ability to recognize asparate 
(Logan and Snyder, 1972; Naito and Ueda, 1985). The 
inhibitory effects on these two types of glutamate 
transport systems, one in the synaptic vesicle mem- 
brane and the other in the presynaptic plasma mem- 
brane, raises the possibility that in vivo short exposure 
to bromocriptine could prolong or potentiate the glu- 
tamate-evoked excitation by inhibiting the reuptake of 
glutamate from the synaptic cleft. Longer exposures 
could lead to hypoglutamatergic transmission by de- 
pleting vesicular glutamate pools. Because bromocrip- 
tine is a selective transport inhibitor with reasonable 
potency, it is also possible that it could serve as a pro- 
totype probe in identifying and characterizing the glu- 
tamate translocator in a purified synaptic vesicle prep- 
aration. 
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